Increased central adiposity and decreased subcutaneous adipose tissue 11β‐hydroxysteroid dehydrogenase type 1 are associated with deterioration in glucose tolerance—A longitudinal cohort study

Increasing adiposity, ageing and tissue‐specific regeneration of cortisol through the activity of 11β‐hydroxysteroid dehydrogenase type 1 have been associated with deterioration in glucose tolerance. We undertook a longitudinal, prospective clinical study to determine if alterations in local glucocorticoid metabolism track with changes in glucose tolerance.

[1]  Eddy J. Bautista,et al.  Integrative Personal Omics Profiles during Periods of Weight Gain and Loss. , 2018, Cell systems.

[2]  A. Drewnowski,et al.  Obesity Pathogenesis: An Endocrine Society Scientific Statement. , 2017, Endocrine reviews.

[3]  W. Dunn,et al.  Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man , 2015, The Journal of clinical endocrinology and metabolism.

[4]  M. Esteve,et al.  Hepatic and visceral adipose tissue 11βHSD1 expressions are markers of body weight loss after bariatric surgery , 2015, Obesity.

[5]  Zaki K Hassan-Smith,et al.  Gender-Specific Differences in Skeletal Muscle 11β-HSD1 Expression Across Healthy Aging. , 2015, The Journal of clinical endocrinology and metabolism.

[6]  K. Manolopoulos,et al.  Tissue specific regulation of glucocorticoids in severe obesity and the response to significant weight loss following bariatric surgery (BARICORT). , 2015, The Journal of clinical endocrinology and metabolism.

[7]  S. Heshka,et al.  Changes in Adipose Tissue Depots and Metabolic Markers Following a 1-Year Diet and Exercise Intervention in Overweight and Obese Patients With Type 2 Diabetes , 2014, Diabetes Care.

[8]  N. Crabtree,et al.  Longitudinal changes in glucocorticoid metabolism are associated with later development of adverse metabolic phenotype. , 2014, European journal of endocrinology.

[9]  H. Gerstein,et al.  Diabetes Risk Among Overweight and Obese Metabolically Healthy Young Adults , 2014, Diabetes Care.

[10]  J. Seckl,et al.  11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. , 2013, Physiological reviews.

[11]  Jeremy W Tomlinson,et al.  11β-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects. , 2013, Endocrine reviews.

[12]  Jarett D. Berry,et al.  Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults , 2012, Obesity.

[13]  G. Lavery,et al.  Novel H6PDH mutations in two girls with premature adrenarche: ‘apparent’ and ‘true’ CRD can be differentiated by urinary steroid profiling , 2012, European journal of endocrinology.

[14]  G. Reynolds,et al.  Lack of Significant Metabolic Abnormalities in Mice with Liver-Specific Disruption of 11β-Hydroxysteroid Dehydrogenase Type 1 , 2012, Endocrinology.

[15]  A. Papavassiliou,et al.  The Expression of Omental 11β-HSD1 Is Not Increased in Severely Obese Women with Metabolic Syndrome , 2012, Obesity Facts.

[16]  E. Lai,et al.  Effects of an 11β‐hydroxysteroid dehydrogenase type 1 inhibitor, MK‐0916, in patients with type 2 diabetes mellitus and metabolic syndrome , 2011, Diabetes, obesity & metabolism.

[17]  P. Feig,et al.  Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. , 2011, Journal of the American Society of Hypertension : JASH.

[18]  Yikyung Park,et al.  Body-mass index and mortality among 1.46 million white adults. , 2010, The New England journal of medicine.

[19]  Udo Hoffmann,et al.  Abdominal Subcutaneous and Visceral Adipose Tissue and Insulin Resistance in the Framingham Heart Study , 2010, Obesity.

[20]  G. Shulman,et al.  Downregulation of ADIPOQ and PPARγ2 Gene Expression in Subcutaneous Adipose Tissue of Obese Adolescents With Hepatic Steatosis , 2010, Obesity.

[21]  A. Veilleux,et al.  Expression of genes related to glucocorticoid action in human subcutaneous and omental adipose tissue , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[22]  A. Veilleux,et al.  Omental adipose tissue type 1 11 beta-hydroxysteroid dehydrogenase oxoreductase activity, body fat distribution, and metabolic alterations in women. , 2009, The Journal of clinical endocrinology and metabolism.

[23]  G. Shulman,et al.  Adipose Overexpression of Desnutrin Promotes Fatty Acid Use and Attenuates Diet-Induced Obesity , 2009, Diabetes.

[24]  R. Rizza,et al.  Liver Is the Site of Splanchnic Cortisol Production in Obese Nondiabetic Humans , 2009, Diabetes.

[25]  P. Stewart,et al.  Reduced glucocorticoid production rate, decreased 5α-reductase activity and adipose tissue insulin sensitization following weight loss , 2008, Diabetes.

[26]  Ramesh Ramakrishnan,et al.  High Throughput Gene Expression Measurement with Real Time PCR in a Microfluidic Dynamic Array , 2008, PloS one.

[27]  W. Inder,et al.  Altered Activity of 11β-Hydroxysteroid Dehydrogenase Types 1 and 2 in Skeletal Muscle Confers Metabolic Protection in Subjects with Type 2 Diabetes , 2007 .

[28]  B. Walker,et al.  Glucocorticoid metabolism within superficial subcutaneous rather than visceral adipose tissue is associated with features of the metabolic syndrome in South African women , 2006, Clinical endocrinology.

[29]  E. Wagner,et al.  Defective Lipolysis and Altered Energy Metabolism in Mice Lacking Adipose Triglyceride Lipase , 2006, Science.

[30]  Jasbir S. Moore,et al.  Weight loss increases 11beta-hydroxysteroid dehydrogenase type 1 expression in human adipose tissue. , 2004, The Journal of clinical endocrinology and metabolism.

[31]  M. Elia,et al.  Influence of short-term dietary weight loss on cortisol secretion and metabolism in obese men. , 2004, European journal of endocrinology.

[32]  E. A. Sims,et al.  Are there persons who are obese, but metabolically healthy? , 2001, Metabolism: clinical and experimental.

[33]  P. Stewart,et al.  Does central obesity reflect “Cushing's disease of the omentum”? , 1997, The Lancet.

[34]  C. Shackleton,et al.  Urinary free cortisone and the assessment of 11β‐hydroxysteroid dehydrogenase activity in man , 1996, Clinical endocrinology.

[35]  D. Milford,et al.  Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11β-hydroxysteroid dehydrogenase type 2 gene , 1996, The Lancet.

[36]  R. Hall,et al.  Relationship of Muscle Apolipoprotein E Expression with Markers of Cellular Stress, Metabolism, and Blood Biomarkers in Cognitively Healthy and Impaired Older Adults , 2023, Journal of Alzheimer's disease : JAD.

[37]  A. Basu,et al.  11β-hydroxysteroid dehydrogenase types 1 and 2 activity in subcutaneous adipose tissue in humans: implications in obesity and diabetes. , 2015, The Journal of clinical endocrinology and metabolism.

[38]  P. Arner,et al.  Adipose triglyceride lipase and hormone-sensitive lipase protein expression is decreased in the obese insulin-resistant state. , 2007, The Journal of clinical endocrinology and metabolism.

[39]  A. Barnett,et al.  11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. , 2004, The Journal of clinical endocrinology and metabolism.

[40]  P. Stewart,et al.  Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion. , 2002, The Journal of clinical endocrinology and metabolism.

[41]  M. Hewison,et al.  Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. , 2002, The Journal of clinical endocrinology and metabolism.